For starters some legwork is necessary and CTIX must be involved. For example finding out if the company is listed on the Frankfurt exchange (reputation wise one of the worst) and whether CTIX sought membership or they became listed because some other entity requested it. Then through legal channels CTIX must request that their stock be removed from trading on that exchange. This can be a big help, but it won't completely eliminate it.. Shorts have a legal standing, but having them adhere to at least US laws is significant. Once they get away from an entity like that, then price becomes the issue. The higher the price the more difficult to maintain huge short positions because the cash needed to hold grows almost exponentially with the price, as losses grow until covered. Whereas other situations only risk the original capital....Uplisting and price growth then become the other significant factors... Not an expert, but I think pretty accurate... CTIX
Excellent post from "I need help"... CTIX pattern is very similar to what may be referred to as the "average" for low priced and advancing bio-pharmas that are not yet revenue, jv, or advanced stage driven in their progression.